Perfluoroundecanoic acid

Synonyms: 全氟十一烷酸; 二十一氟十一烷酸
Perfluoroundecanoic acid 是一种全氟烷基物质 (PFAS),也是一种口服有效的氧化应激诱导剂,可促进巨噬细胞 M2 极化、激活 Wnt/β-catenin 信号通路并增强 β-catenin 的核积累,其诱导的 M2 表型巨噬细胞在体外和体内加速肿瘤进展;此外,它通过氧化应激诱导雄性 Swiss 小鼠的 DNA 损伤、生殖和病理生理功能障碍,通过诱导氧化应激和自噬 (Autophagy) 抑制青春期雄性大鼠的 Leydig 细胞发育,并加速 1 型糖尿病小鼠模型中胰岛炎的发展,可用于卵巢癌、1 型糖尿病和炎症研究。
产品编号: MS-L24617 纯度: 99.85% CAS No.: 2058-94-8 分子式: C11Hf21O2 分子量: 564.09
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
500mg
询价
3-5 天
1g
询价
3-5 天
5g
询价
询价
10g
询价
询价

产品描述

Perfluoroundecanoic acid 是一种全氟烷基物质 (PFAS),也是一种口服有效的氧化应激诱导剂,可促进巨噬细胞 M2 极化、激活 Wnt/β-catenin 信号通路并增强 β-catenin 的核积累,其诱导的 M2 表型巨噬细胞在体外和体内加速肿瘤进展;此外,它通过氧化应激诱导雄性 Swiss 小鼠的 DNA 损伤、生殖和病理生理功能障碍,通过诱导氧化应激和自噬 (Autophagy) 抑制青春期雄性大鼠的 Leydig 细胞发育,并加速 1 型糖尿病小鼠模型中胰岛炎的发展,可用于卵巢癌、1 型糖尿病和炎症研究。

生物实验数据

生物活性 Perfluoroundecanoic acid is a perfluoroalkyl substance (PFAS) and an orally active oxidative stress inducer that promotes macrophage M2 polarization, activates the Wnt/β-catenin signaling pathway, and enhances nuclear accumulation of β-catenin, with the M2-phenotype macrophages induced by it accelerating tumor progression in vitro and in vivo; moreover, it induces DNA damage, reproductive and pathophysiological dysfunction in male Swiss mice through oxidative stress, inhibits Leydig cell development in pubertal male rats by inducing oxidative stress and autophagy (Autophagy), and accelerates the development of insulitis in a mouse model of type 1 diabetes, and can be used for research on ovarian cancer, type 1 diabetes, and inflammation.
体外研究
(In Vitro)

Perfluoroundecanoic acid (2-16 μM,24 小时) 通过增加 M2 标志物 (ARG1、CD163、TGF-β) 的蛋白和 mRNA 水平以及降低 M1 标志物 (iNOS) 的水平,促进 RAW264.7 巨噬细胞的 M2 极化。
Perfluoroundecanoic acid (8 μM,24 小时) 在 RAW264.7 细胞中激活 Wnt/β-catenin 通路,增强 β-catenin 的表达和核转位。
Perfluoroundecanoic acid (8 μM,24 小时) 预处理的 RAW264.7 细胞条件培养基促进 A2780 和 SKOV3 卵巢癌细胞的迁移和侵袭,这一作用可被 β-catenin 抑制剂 ICG001 (MS-P35878) 逆转。

Western Blot Analysis

Cell Line: RAW264.7 cells
Concentration: 2, 4, 8, 16 μM
Incubation Time: 24 h
Result: Increased protein levels of M2 markers (ARG1, CD163) and decreased M1 marker (iNOS), with the most significant changes at 8 μM.
Increased β-catenin protein level and nuclear translocation; no significant changes in p-smad2, p-smad3, p-Akt, p-mTOR, or PPARα.
体内研究
(In Vivo)

Perfluoroundecanoic acid (8 μM 预处理的 RAW264.7 细胞,与 SKOV3 细胞一起腹腔内共同注射,持续 4 周) 增加 BALB/c 裸鼠卵巢癌转移结节的数量和重量。
Perfluoroundecanoic acid (0-10 mg/kg,口服,每日一次,21-35 天) 通过氧化应激和自噬抑制青春期雄性 Sprague-Dawley 大鼠的 Leydig 细胞发育和功能。
Perfluoroundecanoic acid (3-300 μg/L,饮用水中,从交配到妊娠、哺乳直至 30 周龄) 加速 1 型糖尿病小鼠中胰岛炎的发展。
Perfluoroundecanoic acid (0.1-1.0 mg/kg,每天口服,28-35 天) 通过氧化应激诱导雄性 Swiss 小鼠的 DNA 损伤、生殖和病理生理功能障碍。

Animal Model: 5-week-old female BALB/c nude mice were intraperitoneally coinjected pretreated RAW264.7 cells and SKOV3 cells, with observation for 4 weeks
Dosage: 8 μM pretreated RAW264.7 cells
Administration: Co-injected intraperitoneally with SKOV3 cells for 4 weeks
Result: Increased the number and weight of ovarian cancer metastatic nodules.
Reduced the number and weight of ovarian cancer metastatic nodules in the above mouse model when pretreated with β-catenin inhibitor ICG001.
Animal Model: 35 days old Sprague-Dawley rats
Dosage: 1, 5, 10 mg/kg
Administration: p.o. daily for 21-35 days
Result: Reduced serum testosterone at ≥1 mg/kg; no effect on serum estradiol.
Reduced serum LH at ≥1 mg/kg and serum FSH at 5 and 10 mg/kg.
Down-regulated expression of Lhb and Fshb in the pituitary at 5 and/or 10 mg/kg; up-regulated Gnrhr expression at 10 mg/kg.
Reduced Leydig cell number (CYP11A1-positive and HSD11B1-positive) at 5 and 10 mg/kg; no effect on Sertoli cell number.
Down-regulated expression of steroidogenesis-related genes (Lhcgr, Scarb1, Star, Cyp11a1) and their proteins in the testis at various doses.
Reduced sperm in the epididymis caput, corpus, and cauda at 10 mg/kg.
Increased testicular triglyceride levels at 5 and 10 mg/kg; no effect on testicular total cholesterol.
Down-regulated expression of Sod1 and Sod2 in the testis at various doses; increased MDA levels at 10 mg/kg.
Increased LC3B and p62 levels.
Reduced Beclin1 at 5 and 10 mg/kg.
Reduced phosphorylation of mTOR, AKT1, AKT2, and ERK1/2.
Reduced BCL2 levels at 5 and 10 mg/kg; increased BAX level at 10 mg/kg.
Animal Model: Female non-obese diabetic (NOD) mice (offspring of 8-week-old females and 10-week-old males)
Dosage: 3, 30, 300 μg/L in drinking water
Administration: p.o. from mating through gestation, lactation and until 30 weeks of age
Result: Increased pancreatic insulitis grade at 11 weeks of age (300 μg/L).
Increased number of apoptotic cells in pancreatic islets with insulitis grade 0 at 11 weeks of age (300 μg/L).
Reduced peritoneal macrophage phagocytosis at 7 weeks of age (300 μg/L).
Increased ConA-induced IL-2 secretion and decreased LPS-induced IL-6 secretion in splenocytes at 11 weeks of age (3 μg/L).
Showed a trend of increased ConA-induced IL-6 and IFN-γ secretion in splenocytes at 11 weeks of age (300 μg/L).
Had no significant effect on accelerating diabetes development, and low doses (3, 30 μg/L) tended to reduce diabetes incidence.
Animal Model: Male Swiss mice (8 or 13 weeks old)
Dosage: 0.1, 0.3, 0.5, 0.7, 1.0 mg/kg
Administration: p.o. for 28-35 days
Result: Induced significant hepatic DNA damage.
Caused reproductive toxicity: reduced sperm count and motility, increased sperm abnormalities; elevated serum LH and FSH, reduced testosterone; testicular atrophy and histopathological lesions.
Altered hematological parameters: decreased PCV, Hb, platelets, RBC count and indices; increased WBC and neutrophils.
Disrupted clinical biochemistry: elevated AST, ALT, urea, total cholesterol, triglyceride; reduced ALP, albumin, creatinine, HDL.
Induced oxidative stress in liver and testis: increased SOD, CAT, GST, MDA; reduced GPx, GSH.
Caused histopathological lesions in liver (cellular infiltration, venous congestion) and kidney (interstitial congestion, tubular lumen expansion); no spleen lesions.
性状 固体
颜色 White to off-white

化学信息

分子量 564.09
分子式 C11Hf21O2
CAS No. 2058-94-8
别名 全氟十一烷酸; 二十一氟十一烷酸

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 175 mg/mL (310.23 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.7728 mL8.8638 mL17.7277 mL44.3192 mL
5 mM0.3546 mL1.7728 mL3.5455 mL8.8638 mL
10 mM0.1773 mL0.8864 mL1.7728 mL4.4319 mL
15 mM0.1182 mL0.5909 mL1.1818 mL2.9546 mL
20 mM0.0886 mL0.4432 mL0.8864 mL2.2160 mL
25 mM0.0709 mL0.3546 mL0.7091 mL1.7728 mL
30 mM0.0591 mL0.2955 mL0.5909 mL1.4773 mL
40 mM0.0443 mL0.2216 mL0.4432 mL1.1080 mL
50 mM0.0355 mL0.1773 mL0.3546 mL0.8864 mL
60 mM0.0295 mL0.1477 mL0.2955 mL0.7387 mL
80 mM0.0222 mL0.1108 mL0.2216 mL0.5540 mL
100 mM0.0177 mL0.0886 mL0.1773 mL0.4432 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础